Pilot Imaging Study of Leukemia (REALIZE)

U

University of Oklahoma (OU)

Status and phase

Enrolling
Phase 1

Conditions

Acute Lymphocytic Leukemia
Ambiguous Lineage Leukemia or Lymphoma
Myeloma
Acute Myeloid Leukemia

Treatments

Drug: FLT

Study type

Interventional

Funder types

Other

Identifiers

NCT03633955
OU-SCC-REALIZE

Details and patient eligibility

About

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

Full description

This prospective trial is designed to evaluate whether investigational 18F FLT imaging can identify the burden of hematopoietic disease both subjectively (by pattern of hematopoiesis in medullary spaces) and objectively (by SUV determination). Patients undergoing therapy for treatment of high-risk acute leukemia or myeloma will be eligible for this study. Patients may or may not have undergone myeloablative hematopoietic stem cell transplantation. Two cohorts will be accrued: patients with high risk acute leukemia and patients with myeloma. In each cohort, patients will be accrued under two arms: Arm A - patients receiving immunotherapy and Arm B - patients who are receiving standard therapy (not immunotherapy or bone marrow transplant). Therefore, the leukemia cohort will consist of patients accrued in Arm A-L (immunotherapy) or in Arm B-L (standard therapy), and the myeloma cohort will consist of patients accrued in Arm A-M (immunotherapy) or in Arm B-M (standard therapy). Because patients with high risk acute leukemia or myeloma have poor prognosis with high risk for relapse, novel ways to evaluate the success of therapies would be valuable. 18F FLT reveals hematopoietic cell proliferation and can identify residual leukemia disease. On this trial, patients will undergo 18F FLT imaging pre-therapy and during a follow-up visit post-therapy. Patients in both cohorts will be imaged (Termed baseline scan) within one week prior to receiving respective therapies (e.g. immunotherapy or standard therapy) and then imaged approximately 28 days (+/-3 days) after the therapy termed Follow-up scan. After treatment, weekly follow-ups will be conducted for these patients till the follow-up scan (28 days +/-3 days) and then the final follow-up will be conducted post-1-year (after the start of immunotherapy or standard therapy).

Enrollment

60 estimated patients

Sex

All

Ages

4 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 4 to 80 years
  • Evidence of high-risk hematopoietic malignancy with relapsed/refractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma
  • Karnofsky/Lansky score of ≥ 50
  • Agree to use contraceptive measures during study protocol participation (when age appropriate)
  • Patient or parent/guardian capable of providing informed consent.
  • Ability to undergo 18F FLT imaging without sedation
  • Bilirubin < 2.5 mg/dL, AST/ALT <5x upper limit of normal, Serum creatinine < 1.0 or 2x the upper limit of normal (whichever is higher)
  • Pulse oximetry of > 90% on room air
  • Ability to undergo 18F FLT imaging without sedation
  • Anticipated immunotherapy (Arm A to include patients who received immune therapy with co-enrollment on a separate protocol or other immunotherapy) and Arm B, those who received other non-immune therapies to treat their cancers (excludes HSCT but includes chemotherapy or non-HSCT radiotherapy).

Exclusion criteria

  • Patients with uncontrolled infections
  • Pregnancy or lactating
  • History of prior fluorothymidine allergy or intolerance.

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 4 patient groups

Standard therapy - Acute leukemia cohort
Active Comparator group
Description:
The Arm will accrue patients receiving standard therapy from the high-risk acute leukemia cohort (18 patients).
Treatment:
Drug: FLT
Immunotherapy - Acute leukemia cohort
Experimental group
Description:
The Arm will accrue patients receiving immunotherapy from the high-risk acute leukemia cohort (18 patients).
Treatment:
Drug: FLT
Standard therapy - Myeloma cohort
Active Comparator group
Description:
The Arm will accrue patients receiving standard therapy from the myeloma cohort (9 patients).
Treatment:
Drug: FLT
Immunotherapy - Myeloma cohort
Experimental group
Description:
The Arm will accrue patients receiving immunotherapy from the myeloma cohort (9 patients).
Treatment:
Drug: FLT

Trial contacts and locations

3

Loading...

Central trial contact

Heme Onc Lead Nurse

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems